A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight used it ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...

Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...

In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), tirzepatide reduced the risk for worsening heart failure or cardiovascular death regardless of their baseline ...

The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 days ...

New study results found weight loss and diabetes drugs Zepbound and Mounjaro may significantly cut the risk of diabetes in people with prediabetes and obesity, adding to the growing list of diseases ...

Eli Lilly on Thursday said it is pushing for fast-track approval to greenlight diabetes drug tirzepatide, marketed as Mounjaro, for weight loss after promising clinical trial results, adding a ...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...

VIENNA — Tirzepatide (Mounjaro) is cardioprotective in people with type 2 diabetes (T2D) and established atherosclerotic cardiovascular (CV) disease, but not more so than dulaglutide (Trulicity), ...